3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Carcinoma, Renal Cell
2
Uterine Cervical Neoplasms
1
Uterine Cervical Dysplasia
1
Skin Neoplasms
1
Rectal Diseases
1
Pilonidal Sinus
1
Pancreatic Neoplasms
1
Pain, Postoperative
1
Neoplasms
1
Hemorrhage
1
Endometriosis
1
Dysplastic Nevus Syndrome
1
Diverticulitis
1
Crohn Disease
1
Constipation
1
Colonic Diseases
1
Colitis, Ulcerative
1
Carcinoma, Squamous Cell
1
Carcinoma, Basal Cell
1
Breast Neoplasms
1
Bile Duct Neoplasms
1
Interventions
pembrolizumab
23
Nivolumab
22
aldesleukin
21
Cyclophosphamide
20
Ipilimumab
17
Interleukin-2
17
fludarabine
15
fludarabine phosphate
14
cemiplimab
12
Radiotherapy
7
Fluorouracil
7
Dacarbazine
6
binimetinib
5
Vemurafenib
5
Temozolomide
5
Surgical Procedures, Operative
5
Sirolimus
5
Radiation
5
Biopsy
5
Aminolevulinic Acid
5
encorafenib
4
dabrafenib
4
Photochemotherapy
4
Educational Status
4
trametinib
3
sonidegib
3
montanide ISA 51
3
avelumab
3
Tacrolimus
3
Sodium Chloride
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Skin Neoplasms
×
Sutures
×
Clear all
NCT00586040
2009-04-10
PTB
Massachusetts General Hospital
Phase 2
Completed
40 enrolled